Cap Analogs
CAP m7(3'OMeG-LNA)(5')ppp(5')(2'OMe,m6A)pG Sodium Salt
Quick view. An LNA-modified trinucleotide cap analog supplied under a no-CAS sodium-salt identity. A public CAS number is not assigned for this exact form. Catalog target purity: ≥98%. Availability: Inquiry only — contact BX Lab to confirm current availability.
Product profile
CAP m7(3'OMeG-LNA)(5')ppp(5')(2'OMe,m6A)pG Sodium Salt is classified as cap analogs.
CAP m7(3'OMeG-LNA)(5')ppp(5')(2'OMe,m6A)pG Sodium Salt supports in-vitro transcription and capped RNA preparation, including mRNA research and translation studies.
For CAP m7(3'OMeG-LNA)(5')ppp(5')(2'OMe,m6A)pG Sodium Salt, capping outcome depends on polymerase system, cap-to-NTP ratio, transcript design and purification method.
Names and search terms
Confirmed or normalized name variants
- m7(3'-OMeG-LNA)(5')ppp(5')(2'-OMe,m6A)pG trisodium
Physicochemical data
| CAS status | No public CAS assigned in the reviewed sources |
|---|---|
| Supplier-described counterion form | Trisodium |
| Sequence shorthand | m7(3'-OMeG-LNA)(5')ppp(5')(2'-OMe,m6A)pG |
| Covalent InChIKey | XGYMAOAFECDNEE-LPBRTZGOSA-N |
| Covalent InChI | InChI=1S/C35H47N15O24P4/c1-38-24-15-25(40-9-39-24)48(10-41-15)31-21(63-3)20(72-75(55,56)66-5-13-18(51)19(52)30(69-13)49-11-42-16-26(49)43-33(36)45-28(16)53)14(70-31)6-67-76(57,58)73-78(61,62)74-77(59,60)68-8-35-7-65-22(23(35)64-4)32(71-35)50-12-47(2)17-27(50)44-34(37)46-29(17)54/h9-14,18-23,30-32,51-52H,5-8H2,1-4H3,(H10-,36,37,38,39,40,43,44,45,46,53,54,55,56,57,58,59,60,61,62)/t13-,14-,18-,19-,20-,21-,22-,23+,30-,31-,32-,35-/m1/s1 |
| Covalent SMILES | CNc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)([O-])OC[C@@]23CO[C@@H]([C@H](n4c[n+](C)c5c(=O)[nH]c(N)nc54)O2)[C@@H]3OC)[C@@H](OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](O)[C@@H]2O)[C@H]1OC |
| Canonical covalent SMILES | CNc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)([O-])OC[C@@]23CO[C@@H]([C@H](n4c[n+](C)c5c(=O)[nH]c(N)nc54)O2)[C@@H]3OC)[C@@H](OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](O)[C@@H]2O)[C@H]1OC |
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.
Product-specific evaluation notes
Potential advantages
- Cap analog selection can influence capping efficiency, orientation and downstream translation-related performance.
Method limitations
- Capping outcome depends on polymerase system, cap-to-NTP ratio, transcript design and purification method.
These points describe CAP m7(3'OMeG-LNA)(5')ppp(5')(2'OMe,m6A)pG Sodium Salt or its named chemical feature. Broader product-family guidance is maintained on the category page.
Related products
ARCA (m2(7,3'-O)GpppG)
Cap Analogs · CAS: 400806-46-4
BX-CA-0002A(5')ppp(5')(2'-OMeA)pG tetraammonium
Cap Analogs · CAS: N/A
BX-CA-0003m7G(UNA)(5')ppp(5')(2'-OMeA)pG triammonium
Cap Analogs · CAS: N/A
BX-CA-0004m7G(5')vppp(5')(2'-OMeA)pG triammonium
Cap Analogs · CAS: 3038327-80-6
BX-CA-0005CAP 6 m7G(LNA)(5')ppp(5')(2'OMeA)pG Triammonium Salt
Cap Analogs · CAS: N/A
BX-CA-0006CAP 7 m7G(HNA)(5')ppp(5')(2'OMeA)pG Ammonium Salt
Cap Analogs · CAS: N/A
Frequently asked questions
Can the package size for CAP m7(3'OMeG-LNA)(5')ppp(5')(2'OMe,m6A)pG Sodium Salt be customized?
Yes. Share the initial quantity, expected future scale, delivery timeline and packaging preference for review.
What information should be included in a quote request?
Quote catalog number BX-CA-0021, the intended research workflow, required quantity and any additional HPLC, MS or NMR documentation needed.
Product-family literature
These publications provide peer-reviewed context for the Cap Analogs product family and its named chemistry. They are background reading only, not evidence for the exact product, supplied form, lot specification, availability or performance.
Technology platforms
Catalog-derived platform membership for navigating related chemistry and verifiable product sets.